

**TXNRD1 Blocking Peptide (Center)**

Synthetic peptide

Catalog # BP22147c

**Specification****TXNRD1 Blocking Peptide (Center) - Product Information**

Primary Accession [Q16881](#)  
Other Accession [Q62768](#), [Q9MY8](#),  
[Q5NVA2](#)

**TXNRD1 Blocking Peptide (Center) - Additional Information****Gene ID** 7296**Other Names**

Thioredoxin reductase 1, cytoplasmic, TR, 1.8.1.9, Gene associated with retinoic and interferon-induced mortality 12 protein, GRIM-12, Gene associated with retinoic and IFN-induced mortality 12 protein, KM-102-derived reductase-like factor, Thioredoxin reductase TR1, TXNRD1, GRIM12, KDRF

**Target/Specificity**

The synthetic peptide sequence is selected from aa 291-305 of HUMAN TXNRD1

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**TXNRD1 Blocking Peptide (Center) - Protein Information****Name** TXNRD1**TXNRD1 Blocking Peptide (Center) - Background**

Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a combination of interferon-beta and retinoic acid.

**TXNRD1 Blocking Peptide (Center) - References**

Gasdaska P.Y., et al. FEBS Lett. 373:5-9(1995).  
Koishi R., et al. J. Biol. Chem. 272:2570-2577(1997).  
Hofman E.R., et al. Mol. Cell. Biol. 18:6493-6504(1998).  
Rundloef A.-K., et al. Free Radic. Biol. Med. 36:641-656(2004).  
Schuetze N., et al. Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases.

**Synonyms** GRIM12, KDRF**Function**

Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a combination of interferon-beta and retinoic acid.

**Cellular Location**

Cytoplasm. [Isoform 5]: Cytoplasm.

**Tissue Location**

Isoform 1 is expressed predominantly in Leydig cells (at protein level). Also expressed in ovary, spleen, heart, liver, kidney and pancreas and in a number of cancer cell lines Isoform 4 is widely expressed with highest levels in kidney, testis, uterus, ovary, prostate, placenta and fetal liver

**TXNRD1 Blocking Peptide (Center) -  
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)